George Poste
Known title: DirectorCIK: 0001180770
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Exelixis Shares Rise on CABOMETYX Revenue. Exelixis stock has moved higher following reports of strong revenue from its drug CABOMETYX. This performance is relevant as it demonstrates the commercial strength of the company's primary product. The FDA also expanded the label for Merck's Welireg, a competitor in the kidney cancer space, which adds context to the market environment.
Transaction History
| CAI | ▲ Buy | Grant | 1,600 | $25K | 5/29/2026 | View on chart |
| EXEL | ▲ Buy | Grant | 8,367 | $0 | 5/27/2026 | View on chart |
| EXEL | ▼ Sell | Open Market | 60,000 | $2.7M | 5/7/2026 | View on chart |
| CAI | ▲ Buy | Option Exercise | 125,000 | $305K | 8/11/2025 | View on chart |
| CAI | ▼ Sell | Tax Withholding | 48,022 | $1.4M | 8/11/2025 | View on chart |
| CAI | ▼ Sell | Tax Withholding | 91,495 | $2.7M | 8/11/2025 | View on chart |
| EXEL | ▲ Buy | Grant | 9,812 | $0 | 5/29/2025 | View on chart |
| EXEL | ▲ Buy | Option Exercise | 20,634 | $408K | 5/16/2025 | View on chart |
| EXEL | ▼ Sell | Open Market | 20,634 | $949K | 5/16/2025 | View on chart |
| EXEL | ▲ Buy | Option Exercise | 15,874 | $325K | 2/14/2025 | View on chart |
| EXEL | ▼ Sell | Open Market | 15,874 | $551K | 2/14/2025 | View on chart |
| EXEL | ▼ Sell | Open Market | 30,000 | $1.0M | 11/1/2024 | View on chart |
| EXEL | ▼ Sell | Open Market | 33,725 | $907K | 8/8/2024 | View on chart |
| EXEL | ▲ Buy | Grant | 18,838 | $0 | 5/31/2024 | View on chart |
| EXEL | ▲ Buy | Option Exercise | 11,686 | $229K | 5/21/2024 | View on chart |
| EXEL | ▼ Sell | Open Market | 11,686 | $245K | 5/21/2024 | View on chart |
| EXEL | ▲ Buy | Grant | 20,718 | $0 | 6/1/2023 | View on chart |
| EXEL | ▲ Buy | Option Exercise | 40,000 | $252K | 11/29/2022 | View on chart |
| EXEL | ▼ Sell | Open Market | 40,000 | $667K | 11/29/2022 | View on chart |
| EXEL | ▲ Buy | Grant | 19,575 | $0 | 5/26/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
CAI Trades Amid Market Rally Following Google's Nuclear Deal
The S&P 500 and Nasdaq reached record highs, with power stocks rallying after news of Google's nuclear deal. The broader market rally could lift many stocks, including CAI, which trades near its 52‑week low. CAI remains in a neutral technical zone with an RSI near 50 and support at $15.28.
CAI Trades Amid Market Rally Following Google's Nuclear Deal. The S&P 500 and Nasdaq reached record highs, with power stocks rallying after news of Google's nuclear deal. The broader market rally could lift many stocks, including CAI, which trades near its 52‑week low. CAI remains in a neutral technical zone with an RSI near 50 and support at $15.28.